• Company
• Tabrecta/ Rybrevant are expected to enter the market
• by Eo, Yun-Ho Oct 13, 2021 05:47am

• Policy
• MFDS will quickly & thoroughly verify Merck's COVID-19 tx
• by Lee, Tak-Sun Oct 13, 2021 05:46am

• Policy
• ‘Skilarence’ may be reimbursed if it accepts PBAC's price
• by Lee, Hye-Kyung Oct 13, 2021 05:46am

• Policy
• Drug prices are the key to easing the PAH benefit standard
• by Choi-sun Oct 13, 2021 05:46am

• Company
• ‘Rinvoq’ tries AD reimbursement following ‘Olumiant’
• by Eo, Yun-Ho Oct 12, 2021 05:50am

• Policy
• Hanmi's HM15912 is approved for phase 2 in Korea
• by Lee, Tak-Sun Oct 12, 2021 05:50am

• Policy
• Gov “It was the experts’ decision to not list Kymriah”
• by Kim, Jung-Ju Oct 12, 2021 05:49am

• Policy
• The MOHW expressed reluctance to Keytruda's primary benefit
• by Lee, Jeong-Hwan Oct 12, 2021 05:49am

• Company
• SK Bioscience will also produce COVID-19 vaccines next year
• by Chon, Seung-Hyun Oct 12, 2021 05:49am

• Company
• Dupixent reimbursement in pediatric AD is being discussed
• by Eo, Yun-Ho Oct 8, 2021 05:57am